Skip to contentpdufa.bio

HWK-016 (MUC16-directed ADC)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

HWK-016 (MUC16-directed ADC) is a Whitehawk Therapeutics, Inc. program in solid tumors (incl. ovarian cancer). Its next catalyst is a Readout in Q2 2027.

WHWK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Solid tumors (incl. ovarian cancer). Sponsor: Whitehawk Therapeutics, Inc. (WHWK). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027WHWK

Questions

When is HWK-016 (MUC16-directed ADC)'s next FDA decision or readout?

The next tracked catalyst for HWK-016 (MUC16-directed ADC) is a Readout in Q2 2027.

What happened at HWK-016 (MUC16-directed ADC)'s most recent FDA decision?

No FDA decision for HWK-016 (MUC16-directed ADC) is in our archive yet.

What is HWK-016 (MUC16-directed ADC) used for?

In our records HWK-016 (MUC16-directed ADC) is under review or in development for Solid tumors (incl. ovarian cancer).

Who makes HWK-016 (MUC16-directed ADC)?

Whitehawk Therapeutics, Inc. (WHWK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.